Loading...
Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
Khaddour, Karam ; Jonna, Sushma ; Deneka, Alexander Y. ; Patel, Jyoti D. ; Abazeed, Mohamed E. ; ; ;
Khaddour, Karam
Jonna, Sushma
Deneka, Alexander Y.
Patel, Jyoti D.
Abazeed, Mohamed E.
Citations
Altmetric:
Genre
Journal article
Date
2021-06-24
Advisor
Committee member
Department
Cancer and Cellular Biology
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.3390/cancers13133164
Abstract
Epidermal growth factor receptor-targeting tyrosine kinase inhibitors (EGFR TKIs) are the standard of care for patients with EGFR-mutated metastatic lung cancer. While EGFR TKIs have initially high response rates, inherent and acquired resistance constitute a major challenge to the longitudinal treatment. Ongoing work is aimed at understanding the molecular basis of these resistance mechanisms, with exciting new studies evaluating novel agents and combination therapies to improve control of tumors with all forms of EGFR mutation. In this review, we first provide a discussion of EGFR-mutated lung cancer and the efficacy of available EGFR TKIs in the clinical setting against both common and rare EGFR mutations. Second, we discuss common resistance mechanisms that lead to therapy failure during treatment with EGFR TKIs. Third, we review novel approaches aimed at improving outcomes and overcoming resistance to EGFR TKIs. Finally, we highlight recent breakthroughs in the use of EGFR TKIs in non-metastatic EGFR-mutated lung cancer.
Description
Citation
Khaddour K, Jonna S, Deneka AY, Patel JD, Abazeed ME, Golemis EA, Borghaei H, Boumber Y. Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers. 2021 Jun 24;13:3164. doi:10.3390/cancers13133164.
Citation to related work
MDPI
Has part
Cancers, Vol. 13
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
